Article
<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
2025-09-21
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Introduction</h4> RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS , HRAS , and NRAS. Whether homologous RRAS / RRAS2 mutations are oncogenic and actionable drivers in lung cancer remains underexplored. <h4>Methods</h4> An institutional cohort of 8,488 non-small cell lung carcinomas (NSCLC) sequenced...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d48c57bf-ecdf-5bd6-ab47-08ff5c3d7177
- DOI
- 10.1101/2025.09.19.677259
